Gilead Sciences (GILD) Given Daily Coverage Optimism Score of 0.13
Media headlines about Gilead Sciences (NASDAQ:GILD) have been trending somewhat positive on Monday, Accern reports. Accern ranks the sentiment of press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Gilead Sciences earned a news impact score of 0.13 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 46.9727575470222 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the media headlines that may have impacted Accern Sentiment Analysis’s analysis:
- Gilead Sciences (GILD) Raised to Hold from a Sell (investorplace.com)
- Oppenheimer Holdings Weighs in on Gilead Sciences, Inc.’s Q3 2017 Earnings (GILD) (americanbankingnews.com)
- Leerink Swann Equities Analysts Raise Earnings Estimates for Gilead Sciences, Inc. (GILD) (americanbankingnews.com)
- Bitcoin vs. Biotech: Which Is the Smarter Investment? (finance.yahoo.com)
- Gilead Sciences, Inc. (GILD) Coverage Initiated at Jefferies Group LLC (americanbankingnews.com)
Several research analysts recently commented on the stock. ValuEngine raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Thursday, September 7th. TheStreet raised shares of Gilead Sciences from a “c+” rating to a “b-” rating in a report on Thursday, September 7th. Zacks Investment Research downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating in a report on Monday, September 11th. Vetr downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating and set a $86.44 price objective for the company. in a report on Monday, September 4th. Finally, Morgan Stanley reaffirmed an “equal weight” rating and issued a $83.00 price objective (up from $77.00) on shares of Gilead Sciences in a report on Friday. Twelve investment analysts have rated the stock with a hold rating and twenty-one have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $85.66.
Gilead Sciences (GILD) traded down 0.19% during mid-day trading on Monday, hitting $81.98. 3,959,787 shares of the stock were exchanged. The company has a 50-day moving average of $81.25 and a 200-day moving average of $71.82. The stock has a market capitalization of $107.06 billion, a PE ratio of 8.90 and a beta of 1.14. Gilead Sciences has a 52 week low of $63.76 and a 52 week high of $86.27.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.11 by $0.45. The firm had revenue of $7.14 billion during the quarter, compared to analysts’ expectations of $6.35 billion. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The company’s revenue for the quarter was down 8.2% compared to the same quarter last year. During the same period in the prior year, the company posted $3.08 earnings per share. On average, equities analysts predict that Gilead Sciences will post $8.75 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which was paid on Thursday, September 28th. Investors of record on Friday, September 15th were given a dividend of $0.52 per share. The ex-dividend date was Thursday, September 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.54%. Gilead Sciences’s dividend payout ratio is 22.58%.
In related news, EVP Gregg H. Alton sold 40,000 shares of the company’s stock in a transaction on Friday, July 21st. The shares were sold at an average price of $74.00, for a total transaction of $2,960,000.00. Following the completion of the transaction, the executive vice president now owns 137,488 shares in the company, valued at $10,174,112. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction on Tuesday, August 1st. The stock was sold at an average price of $75.86, for a total transaction of $5,563,041.38. Following the transaction, the insider now owns 3,199,969 shares of the company’s stock, valued at approximately $242,749,648.34. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 486,819 shares of company stock valued at $39,298,919. 1.30% of the stock is owned by company insiders.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.